Central Nervous System Cancer

Adolescent and young adult patients with central nervous system tumors who lived farther from the reporting hospital had a lower risk for death than those who lived closer, according to study results published in Journal of Neuro-Oncology.

Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse midline glioma showed tumor regression and improvement in neurologic symptoms, according to early results of a phase 1 study.

Michael E. Salacz, MD, has been appointed director of the neuro-oncology program at Rutgers Cancer Institute of New Jersey.